Abstract
In the recent issue of Nature Communications (2023 Nov 30;14(1):7908), Xue et. al. reported a very interesting and significant discovery of a possible DCAF11 ligand chemotype that could be used as the “warhead” to design bifunctional compounds for targeted degradation via engaging the E3 ligase DCAF11. The discovery is of importance to the targeted protein degradation field and was inspired by previous reports suggesting that similar compounds may also engage the autophagosome protein LC3 for degradation and function as autophagy-tethering compounds (ATTECs), which seem to be inconsistent with the DCAF11 findings. We think that the conclusions based on these data are not necessarily mutually exclusive. After performing additional experiments and analyses, we would like to discuss some possibilities explaining such discrepancies and make a few points of clarification.
Introduction
Targeted Protein Degradation (TPD) is a transformative field in drug discovery, traditionally dominated by PROTACs that hijack the ubiquitin-proteasome system. Recently, Autophagy-Tethering Compounds (ATTECs) have emerged as a complementary strategy, directing "undruggable" targets—including large protein aggregates or organelles—to the lysosome via the autophagy pathway.
A recent high-profile study identified a specific chemical scaffold, arylidene-indolinones, as a ligand for the E3 ligase DCAF11, and argued against its previously reported role as an LC3-binding ATTEC. This created a perceived conflict: does this "warhead" utilize the proteasome or the autophagy pathway? This paper seeks to resolve the discrepancy by demonstrating that these molecules are versatile ligands capable of engaging both machineries, with the choice of pathway determined by the specific target being degraded.
Biophysical Validation of LC3 Binding
The authors employed sensitive biophysical assays to re-evaluate the binding of these compounds to LC3B. While previous studies using Fluorescence Polarization (FP) failed to detect interaction, Surface Plasmon Resonance (SPR) and Bio-layer Interferometry (BLI) clearly demonstrated binding with micromolar affinity ($K_d$ ranging from ~7 $\mu M$ to ~170 $\mu M$).
As shown in the binding data, both GW5074 and its analog AN1 exhibit clear dose-dependent responses. The authors suggest that the choice of assay is critical; the high concentrations required for FP may have masked the binding signal, whereas SPR and BLI provide the necessary sensitivity to detect these interactions.
Structural Evidence via NMR Spectroscopy
To provide atomic-level confirmation of the physical interaction, the authors used 2D-NMR Heteronuclear Single Quantum Coherence (HSQC) spectroscopy. This technique provides a structural "fingerprint" of the protein's backbone. Upon addition of the compounds, specific peaks in the LC3B spectrum shifted, indicating direct binding and localized structural changes.
The "Dual-Warhead" Mechanism
Rather than being mutually exclusive, the data suggests that arylidene-indolinones are "promiscuous" ligands. They can engage different degradation machineries depending on the cellular context and the target protein. Large, bulky targets like mutant Huntingtin (mHTT) aggregates are physically difficult for the proteasome to process. In these cases, the compounds naturally favor the autophagy pathway (ATTEC mechanism), even if they possess the theoretical capacity to bind an E3 ligase.
This was further validated by pathway inhibition experiments. In cellular models, the degradation of mHTT was significantly blocked by the autophagy inhibitor Chloroquine, but remained unaffected by the proteasome inhibitor MG132. Furthermore, the authors directly observed the formation of a ternary complex (LC3-compound-mHTT) using Oblique-Incidence Reflectivity Difference (OI-RD), proving the "bridge" mechanism required for ATTECs.
Conclusion
This work reconciles the scientific dispute regarding arylidene-indolinone warheads. By demonstrating that these molecules can bind both DCAF11 and LC3, the authors show they are dual-mechanism degraders. This versatility is a strength, allowing for the degradation of a wider variety of targets through the most appropriate cellular pathway. Future optimization of these scaffolds may improve their affinity and selectivity, further expanding the toolkit for targeted protein degradation.
Summary updated